Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/31/2012 - 2:02pm.

  2. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... has been combined with other novel agents such as lenalidomide , histone deacetylase inhibitors and growth factors in the hope ...

    Research Article last updated 05/14/2013 - 2:48pm.

  5. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

    ... Purpose:  The drugs, lenalidomide , bortezomib, and dexamethasone, are approved by the FDA. They ... approved by the FDA for the treatment of multiple myeloma. Lenalidomide is approved for use with dexamethasone for patients with multiple ...

    Clinical Trial last updated 05/23/2016 - 3:45pm.

  6. Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (UF-BMT-MRD-101)

    ... side effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who have a small amount of ... Associated Drug(s):  Lenalidomide Phase:  Phase 1 ...

    Clinical Trial last updated 04/29/2016 - 2:38pm.

  7. Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional

    ... value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an ...

    Research Article last updated 08/07/2013 - 9:18am.

  8. Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes

    ... of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their ...

    Research Article last updated 01/03/2013 - 9:57am.

  9. Myelodysplastic syndromes: an update on molecular pathology.

    ... hypomethylating drugs, immunomodulatory agents such as lenalidomide , and immunosuppressive drugs aimed at reversing the specific ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. MDS Drug Therapy

    ... and high-risk patients with all sub-types of MDS Lenalidomide (Revlimid®) for transfusion-dependent MDS patients with ... Lenalidomide (Revlimid®) Lenalidomide ...

    Topic section last updated 03/10/2016 - 11:26pm.